514 reduced visceral fat by 12% in Phase 2b
A Phase 2b trial for the investigational drug CBL-514 showed a 12% reduction in visceral fat among a small subgroup of participants. The drug, which induces fat cell apoptosis, is currently undergoing further testing but has not yet received regulatory approval.
Why it matters
This represents a potential new approach to obesity treatment, distinct from current GLP-1 medications, though results are preliminary.
The result was observed in a small MRI subgroup four weeks after the end of the course of injections
The investigational CBL-514 injection, in a small MRI subgroup of a Phase 2b trial, demonstrated an average reduction in visceral fat volume of 12.01% four weeks after completion of the treatment course. The new analysis was reported on 2 October by the EASD and the developer, Caliway; the drug is already being studied in a Phase 3 trial, but it has not been approved and is not a proven treatment for obesity.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in